Skip to content
PubMed This is a summary of 10 peer-reviewed journal articles Updated
Endocrinology

Validation & Orientation: Understanding McCune-Albright Syndrome

At a Glance

McCune-Albright syndrome is a rare condition caused by a random genetic change early in development that affects only some cells. Symptoms vary and may include bone changes, café-au-lait skin patches, and excess hormones; people do not need all three features for diagnosis.

Receiving a diagnosis of McCune-Albright Syndrome (MAS) often marks the end of a long and confusing search for answers. For many families and patients, this ‘diagnostic odyssey’ can last years, with some people waiting decades or receiving several incorrect diagnoses before MAS is identified [1][2]. Understanding that your experience is part of a rare but documented medical journey can be a powerful step toward taking control of your care.

A Rare and Unique Condition

McCune-Albright Syndrome is an exceptionally rare condition. While precise numbers are difficult to track because some cases are very mild and may go undiagnosed, it is estimated to affect between 1 in 100,000 and 1 in 1,000,000 people [3][4].

MAS is a mosaic disorder, meaning it is not something you ‘catch’ or inherit from your parents, nor is it something you can pass on to your children [5]. It is caused by a random genetic change (a mutation) that happens very early in development, shortly after conception. Because this change occurs after the egg is fertilized, it only affects some cells in the body while others remains typical. This mixture of affected and unaffected cells is called mosaicism [5][6].

Why Every Patient is Different

The ‘mosaic’ nature of MAS is why no two patients look exactly alike. The severity and symptoms depend entirely on where the affected cells ended up as the body grew, the timing of the mutation, and the amount of mosaicism in different tissues [5].

  • Location and Timing: If the affected cells are in the bones, skin, and hormone-producing glands, the patient may have the classic triad of symptoms. If they are only in one or two areas, the symptoms will be more focused [5][7].
  • Variable Severity: Some individuals have severe multi-system disease with extensive bone involvement or early-onset hormone issues, while some people have limited FD/MAS involvement. (Note: an isolated café-au-lait macule is common in the general population and does not, on its own, mean someone has MAS, though it may prompt assessment) [6].
  • Asynchronous Development: Symptoms do not always appear all at once. For example, a child may be born with a skin spot but not develop bone issues or hormonal changes until several years later [8].

Defining the Diagnosis

Doctors traditionally look for three ‘cardinal’ features to diagnose MAS, though you do not need all three to have the condition. Most clinical guidelines note that a diagnosis is often supported clinically if at least two of the following typical features are present [7][9]:

  1. Fibrous Dysplasia (FD): A condition where typical bone is replaced by weaker, fibrous tissue.
  2. Café-au-lait Macules: Flat, light-brown skin patches that often have irregular borders (sometimes described as looking like the ‘Coast of Maine’).
  3. Hyperfunctioning Endocrinopathies: Glands that produce too many hormones, leading to issues like early puberty (precocious puberty), thyroid problems, or growth hormone excess [5].

Navigating the Emotional Impact

It is natural to feel a wide range of emotions—from relief at finally having a name for your symptoms to fear about what the future holds. The unpredictability of a mosaic condition can be particularly challenging. Because the disease can change as a person grows, families often live in a state of active ‘watchful waiting’ [8][2].

Common experiences include:

  • Frustration: Feeling unheard during the long search for a diagnosis [1].
  • Uncertainty: Worrying about which symptoms might appear next or how severe they will be [6].
  • Isolation: Dealing with a disease so rare that even some doctors have never seen it.

While the medical team focuses on the physical symptoms, acknowledging the psychological toll is just as important. Many patients find strength in connecting with multidisciplinary care teams who understand the complexity of the syndrome and can provide both medical and emotional support [5][10]. As care moves forward, your plan will be tailored to your specific ‘mosaic’ pattern, focusing on the symptoms that affect you most while proactively monitoring for others.

Common questions in this guide

What is McCune-Albright syndrome?
McCune-Albright syndrome is a rare condition caused by a random genetic change early in development. It affects only some cells in the body, so symptoms can involve different tissues and vary widely from person to person.
Is McCune-Albright syndrome inherited from a parent?
Usually, no. McCune-Albright syndrome results from a genetic change that occurs shortly after conception rather than from a change passed down by a parent, and it is not something a person passes on to their children.
What are the main features of McCune-Albright syndrome?
The typical features are fibrous dysplasia, café-au-lait skin patches, and hormone-producing glands that are too active. Hormone-related problems can include early puberty, thyroid problems, or growth hormone excess.
Do you need all three features to be diagnosed with MAS?
No. A person does not need to have all three typical features, and doctors often support a clinical diagnosis when at least two are present. The diagnosis is considered in the context of the person's findings and affected body systems.
Why can McCune-Albright syndrome look different in each person?
The condition affects only some cells, and the location, timing, and amount of affected tissue vary. These differences help explain why one person may have bone, skin, and hormone-related features while another has involvement in only one or two areas.
Can new McCune-Albright syndrome symptoms appear as a child grows?
Yes. Features may not appear at the same time; for example, a skin patch may be present before bone or hormone-related problems develop. Ongoing, individualized monitoring helps the care team watch for changes over time.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on McCune-Albright syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my diagnosis (or my child's) meet the 'two out of three' clinical criteria, and which specific features are currently active?
  2. 2.Given that MAS is mosaic, are there specific systems (like the thyroid or adrenal glands) we should screen now even if there are no symptoms?
  3. 3.Can you explain the 'asynchronous' nature of MAS—what signs should I watch for that might indicate a new area of involvement?
  4. 4.Was the genetic testing done on blood or affected tissue, and does that result change how we monitor the condition?
  5. 5.Can you refer us to a multidisciplinary center or a team that includes specialists in endocrinology, orthopedics, and psychology?

References

References (10)
  1. 1

    Diagnostic journey for individuals with fibrous dysplasia / McCune albright syndrome (FD/MAS).

    Song K, Shrestha R, Delaney H, et al.

    Orphanet journal of rare diseases 2024; (19(1)):50 doi:10.1186/s13023-024-03036-w.

    PMID: 38326833
  2. 2

    McCune-Albright syndrome onset with vaginal bleeding.

    Van Doan N, Minh Duc N, Kim Ngan V, Van Anh N

    BMJ case reports 2021; (14(7)) doi:10.1136/bcr-2021-243401.

    PMID: 34281944
  3. 3

    Multidisciplinary approach and clinical management of McCune-Albright syndrome.

    Wang J, Sang Y

    Frontiers in endocrinology 2026; (17()):1786683 doi:10.3389/fendo.2026.1786683.

    PMID: 42006260
  4. 4

    Early Manifestation of McCune-Albright Syndrome in a 32-Month-Old Female: A Rare Case Report.

    Makhlouf TZ, Mahareeq MS, Abumazen A, et al.

    Journal of investigative medicine high impact case reports 2025; (13()):23247096251367692 doi:10.1177/23247096251367692.

    PMID: 40842264
  5. 5

    The Clinical Spectrum of McCune-Albright Syndrome and Its Management.

    Spencer T, Pan KS, Collins MT, Boyce AM

    Hormone research in paediatrics 2019; (92(6)):347-356 doi:10.1159/000504802.

    PMID: 31865341
  6. 6

    Neonatal McCune-Albright Syndrome: A Unique Syndromic Profile With an Unfavorable Outcome.

    Corsi A, Cherman N, Donaldson DL, et al.

    JBMR plus 2019; (3(8)):e10134 doi:10.1002/jbm4.10134.

    PMID: 31485549
  7. 7

    McCune-Albright Syndrome: A Case Report and Review of Literature.

    Nicolaides NC, Kontou M, Vasilakis IA, et al.

    International journal of molecular sciences 2023; (24(10)) doi:10.3390/ijms24108464.

    PMID: 37239810
  8. 8

    [McCune-Albright syndrome revealed by Blaschko-linear café-au-lait spots on the back].

    Jung AJ, Soskin S, Paris F, Lipsker D

    Annales de dermatologie et de venereologie 2016; (143(1)):21-6.

    PMID: 26610360
  9. 9

    Craniofacial fibrous dysplasia and aneurismal bone cyst in a patient with McCune-Albright syndrome. A case report and review of the literature.

    Castro Castro J, Villa Fernández JM, Agulleiro Díaz JP

    Neurocirugia 2023; (34(5)):268-272 doi:10.1016/j.neucie.2022.09.002.

    PMID: 36192338
  10. 10

    Improving patient outcomes in fibrous dysplasia/McCune-Albright syndrome: an international multidisciplinary workshop to inform an international partnership.

    Boyce AM, Turner A, Watts L, et al.

    Archives of osteoporosis 2017; (12(1)):21 doi:10.1007/s11657-016-0271-6.

    PMID: 28243882

This page is for informational purposes only and does not constitute medical advice about McCune-Albright syndrome. Your endocrinology and other specialists can interpret your or your child's findings and recommend appropriate monitoring.